The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 Therapeutic
The emergence and global impact of COVID-19 has focused the scientific and medical community on the pivotal influential role of respiratory viruses as causes of severe pneumonia, on the understanding of the underlying pathomechanisms, and on potential treatment for COVID-19. The latter concentrates...
Main Authors: | Ludwig Aigner, Frank Pietrantonio, Diana Marisa Bessa de Sousa, Johanna Michael, Daniela Schuster, Herbert Anton Reitsamer, Horst Zerbe, Michael Studnicka |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-12-01
|
Series: | Frontiers in Molecular Biosciences |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmolb.2020.610132/full |
Similar Items
-
The Leukotriene Receptor Antagonist Montelukast Attenuates Neuroinflammation and Affects Cognition in Transgenic 5xFAD Mice
by: Johanna Michael, et al.
Published: (2021-03-01) -
Leukotriene Signaling as a Target in α-Synucleinopathies
by: Katharina Strempfl, et al.
Published: (2022-02-01) -
Microglia depletion diminishes key elements of the leukotriene pathway in the brain of Alzheimer’s Disease mice
by: J. Michael, et al.
Published: (2020-08-01) -
Cognitive Effects of Montelukast: A Pharmaco-EEG Study
by: Fabian Schwimmbeck, et al.
Published: (2021-04-01) -
Effect of a leukotriene receptor antagonist pranlukast hydrate, on airway inflammation airway hyperresponsiveness in patients with moderate to severe asthma
by: Kiyoko Wada, et al.
Published: (2000-01-01)